252 related articles for article (PubMed ID: 36098519)
21. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
[TBL] [Abstract][Full Text] [Related]
23. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
24. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.
Miyazaki T; Hosogaya N; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Ozawa Y; Shiko Y; Inaba Y; Kurokawa T; Hanaoka H; Iwanami S; Kim K; Iwami S; Watashi K; Miyazawa K; Umeyama T; Yamagoe S; Miyazaki Y; Wakita T; Sumiyoshi M; Hirayama T; Izumikawa K; Yanagihara K; Mukae H; Kawasuji H; Yamamoto Y; Tarumoto N; Ishii H; Ohno H; Yatera K; Kakeya H; Kichikawa Y; Kato Y; Matsumoto T; Saito M; Yotsuyanagi H; Kohno S
Microbiol Spectr; 2023 Jun; 11(3):e0431122. PubMed ID: 37140398
[TBL] [Abstract][Full Text] [Related]
25. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
[TBL] [Abstract][Full Text] [Related]
27. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
Feld JJ; Kandel C; Biondi MJ; Kozak RA; Zahoor MA; Lemieux C; Borgia SM; Boggild AK; Powis J; McCready J; Tan DHS; Chan T; Coburn B; Kumar D; Humar A; Chan A; O'Neil B; Noureldin S; Booth J; Hong R; Smookler D; Aleyadeh W; Patel A; Barber B; Casey J; Hiebert R; Mistry H; Choong I; Hislop C; Santer DM; Lorne Tyrrell D; Glenn JS; Gehring AJ; Janssen HLA; Hansen BE
Lancet Respir Med; 2021 May; 9(5):498-510. PubMed ID: 33556319
[TBL] [Abstract][Full Text] [Related]
28. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
Cao B; Wang Y; Lu H; Huang C; Yang Y; Shang L; Chen Z; Jiang R; Liu Y; Lin L; Peng P; Wang F; Gong F; Hu H; Cheng C; Yao X; Ye X; Zhou H; Shen Y; Liu C; Wang C; Yi Z; Hu B; Xu J; Gu X; Shen J; Xu Y; Zhang L; Fan J; Tang R; Wang C
N Engl J Med; 2024 Jan; 390(3):230-241. PubMed ID: 38231624
[TBL] [Abstract][Full Text] [Related]
29. Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor.
Katsube T; Kezbor S; Shimizu R; Kubota R
Infect Dis Ther; 2024 Mar; 13(3):597-607. PubMed ID: 38460082
[TBL] [Abstract][Full Text] [Related]
30. Computational Estimation of Residues Involving Resistance to the SARS-CoV-2 Main Protease Inhibitor Ensitrelvir Based on Virtual Alanine Scan of the Active Site.
Mizuno A; Nakayoshi T; Kato K; Kurimoto E; Oda A
Biol Pharm Bull; 2024; 47(5):967-977. PubMed ID: 38763751
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care.
Rabanal Basalo A; Navarro Pablos M; Viejo Pinero N; Vila Méndez ML; Molina Barcena V; Montilla Bernabé A; Villanueva Morán MDP; Blanco Gallego AM; Guirao Sánchez C; Juárez Antón S; Fernández Rodríguez Á; Revuelta Puigdollers ML; Sarriá Sánchez MT; Martín Alegre C; Martínez Álvarez MÁ; Mestre de Juan M; Mielgo Salvador R; Gijón Seco MT; Saníger Herrera JM; Rodríguez Jiménez ME; Navas de la Peña B; Santa Cruz Hernández J; Abad Esteban AM; Díaz Martín R; García Pérez L; Herrero Vanrell P; Arias de Saavedra Criado MI; Vaquero Vinent A; López Gómez V; Montegrifo Rentero VM; Simón Miguel L; Campo Martos I; Ortiz Zamorano S; Izquierdo Zamarriego MJ; Vázquez Carrión I; López Valero RM; Gil C; Martínez A; Soler López B
Ann Med; 2023; 55(2):2268535. PubMed ID: 37847999
[TBL] [Abstract][Full Text] [Related]
32. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
33. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.
Carrouel F; Valette M; Gadea E; Esparcieux A; Illes G; Langlois ME; Perrier H; Dussart C; Tramini P; Ribaud M; Bouscambert-Duchamp M; Bourgeois D
Clin Microbiol Infect; 2021 Oct; 27(10):1494-1501. PubMed ID: 34044151
[TBL] [Abstract][Full Text] [Related]
34. Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
Bouzidi HS; Driouich JS; Klitting R; Bernadin O; Piorkowski G; Amaral R; Fraisse L; Mowbray CE; Scandale I; Escudié F; Chatelain E; de Lamballerie X; Nougairède A; Touret F
Antiviral Res; 2024 Feb; 222():105814. PubMed ID: 38272321
[TBL] [Abstract][Full Text] [Related]
35. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
36. A Phase 2 Randomized Trial Evaluating the Antiviral Activity and Safety of the Direct-Acting Antiviral Bemnifosbuvir in Ambulatory Patients with Mild or Moderate COVID-19 (MOONSONG Study).
Boffito M; Dolan E; Singh K; Holmes W; Wildum S; Horga A; Pietropaolo K; Zhou XJ; Clinch B; Collinson N; Ukachukwu V
Microbiol Spectr; 2023 Aug; 11(4):e0007723. PubMed ID: 37338393
[TBL] [Abstract][Full Text] [Related]
37. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
38. Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Holubar M; Subramanian A; Purington N; Hedlin H; Bunning B; Walter KS; Bonilla H; Boumis A; Chen M; Clinton K; Dewhurst L; Epstein C; Jagannathan P; Kaszynski RH; Panu L; Parsonnet J; Ponder EL; Quintero O; Sefton E; Singh U; Soberanis L; Truong H; Andrews JR; Desai M; Khosla C; Maldonado Y
Clin Infect Dis; 2022 Nov; 75(11):1883-1892. PubMed ID: 35446944
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
40. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
